摘要
目的:评价乙型肝炎肝硬化患者应用拉米夫定联合阿德福韦酯治疗的临床效果。方法:选取2009年1月至2013年1月广州市第一人民医院收治的乙型肝炎肝硬化患者177例,随机分为两组,其中观察组89例,应用拉米夫定联合阿德福韦酯治疗,对照组88例,仅选用拉米夫定治疗,观察并比较两组患者HBV-DNA转阴率、肝功能指标、凝血酶原时间活动度(PTA)变化、耐药率和不良反应。结果:观察组HBV-DNA、肝功能与PTA变化、耐药率等方面均明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论:乙型肝炎肝硬化患者应用拉米夫定联合阿德福韦酯治疗的临床效果好,病毒转阴时间短,耐药率低,值得临床推广应用。
OBJECTIVE：To evaluate the clinical efficacy of lamivudine plus adefovir in patients with hepatitis B and liver cirrhosis. METHODS： 177 patients with liver cirrhosis admitted to Guangzhou Municipal First People＇s Hospital from January 2009 to January 2013 were randomly divided into two groups, with 89 cases in the observation group treated with lamivudine plus adefovir and 88 cases in the control group treated with adefovir alone. The two groups were compared with regard to rate of negative-returning rate of HBV-DNA, indicators of liver function, prothrombin time activity （PTA） , drug resistance and adverse drug reactions. RESULTS： The observation group was significantly better than in the control group with regard to negative-returning rate of HBV-DNA, indicators of liver function, prothrombin time activity （PTA） and drug resistance ete, with significant differences noted between the two groups （P 〈 0. 05 ）. CONCLUSION ： Treatment of patients with hepatitis B and liver cirrhosis using lamivudine plus adefovir resulted in noticeable efficacy, short virus negative-returning time and low drug resistance, which thus is worthy of clinical recommendation.
出处
《中国医院用药评价与分析》
2015年第4期496-498,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
